TransCode Therapeutics and Akribion Genomics Report Proof-Of-Concept Laboratory Studies In Human Cells; Say Studies To Date 'suggest that Akribion's G-dase E ribonucleoprotein complexes could be conjugated to TransCode's TTX delivery platform, suggesting that the drug candidate could be formulated as intended.'
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics and Akribion Genomics have announced successful proof-of-concept laboratory studies in human cells. These studies suggest that Akribion's G-dase E ribonucleoprotein complexes can be conjugated to TransCode's TTX delivery platform, indicating the potential for the drug candidate to be formulated as intended.
March 11, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransCode Therapeutics, involved in a promising partnership with Akribion Genomics, has shown positive results in proof-of-concept studies, suggesting potential for their drug candidate's formulation.
The successful proof-of-concept studies between TransCode Therapeutics and Akribion Genomics indicate a significant step forward in the development of their drug candidate. This positive news could lead to increased investor confidence in RNAZ, potentially driving up its stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90